Statins have also demonstrated the potential to reduce the risk of AD by upregulating hepatic LRP1 and LDL receptor expression, which is mediated by sterol response element-binding protein-2 (Moon et al., 2011; Zissimopoulos et al., 2017). Here, LDLR is linked to Alzheimer disease.